Skip to Main Content

The CLARICOR Trial: Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease

This study has been completed.

Sponsor:

Collaborators:

Danish Heart Foundation

Copenhagen Hospital Corporation

The Danish Medical Research Council

The 1991 Pharmacy Foundation

Abbott

Information provided by:

Copenhagen Trial Unit, Center for Clinical Intervention Research

ClinicalTrials.gov Identifier:

NCT00121550

First received: July 13, 2005

Last updated: May 4, 2006

Last verified: September 1999

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	September 2002
Estimated Primary Completion Date:	No date given

Publications:

Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helo OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjoller E, Lind I, Nielsen H, Petersen L, Gluud C; CLARICOR Trial Group. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ. 2006 Jan 7;332(7532):22-7. Epub 2005 Dec 8. Erratum in: BMJ. 2006 Jan 21;332(7534):151.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Winkel P, Hilden J, Fischer Hansen J, Hildebrandt P, Kastrup J, Kolmos HJ, Kjøller E, Jespersen CM, Gluud C, Jensen GB; CLARICOR Trial Group. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective? Cardiology. 2011;118(1):63-7. Epub 2011 Mar 26.

Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt P, Jensen GB, Hilden J, Jespersen CM, Kjøller E, Kolmos HJ, Gluud C, Kastrup J; CLARICOR Trial Group. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. Scand J Clin Lab Invest. 2011 Feb;71(1):52-62. Epub 2010 Nov 25.

Jensen GB, Hilden J, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Jespersen CM, Gluud C; CLARICOR Trial Group. Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. J Cardiovasc Pharmacol. 2010 Feb;55(2):123-8.